Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial.
Steve BoudewijnsMartine BloemendalNienke de HaasHarm WestdorpKalijn Fredrike BolGhaith BakdashErik H J G AarntzenW Joost LesterhuisMark A J GorrisAlexandra CroockewitLieke L van der WoudeMichelle M van RossumMarieke WelzenAnna de GoedeStanleyson V HatoWinette T A van der GraafCornelis J A PuntRutger H T KoornstraWinald R GerritsenCarl G FigdorIngrid Jolanda M De VriesPublished in: Cancer immunology, immunotherapy : CII (2020)
Combination of DC vaccination and cisplatin in melanoma patients is feasible and safe, but does not seem to result in more tumor-specific T cell responses or improved clinical outcome, when compared to DC vaccination monotherapy.